Advertisement

Investigational New Drugs

, Volume 25, Issue 1, pp 49–55 | Cite as

Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study

  • Dahua Zhang
  • Thomas Pier
  • Douglas G. McNeel
  • George Wilding
  • Andreas FriedlEmail author
Phase I Studies

Summary

Purpose: The integrin αvβ3 is an adhesion molecule expressed by proliferating endothelial cells and antibodies blocking this integrin inhibit angiogenesis in preclinical models. MEDI-522 is a second generation humanized anti-αvβ3 antibody designed for antiangiogenic therapy. The purpose of this study was to examine potential effects of this agent on blood vessels.

Experimental design: In a phase I dose escalation study, MEDI-522 was administered by weekly infusions to 25 adult patients with advanced solid organ malignancies. As a surrogate angiogenesis assay, a wound was created by punch biopsy of the arm skin. This wound site was re-biopsied after a 7-day interval. Dual-label immunofluorescence experiments followed by computer-assisted image analysis were conducted to analyze the vasculature.

Results: Sequential pretreatment and 4-week treatment skin biopsy pairs were available on 4 patients, who had received 6 or 10 mg/kg of MEDI-522. MEDI-522 was detected in the dermal blood vessels as well as the dermal interstitium both in intact and wounded skin sites following treatment. No statistically significant difference was found between pretreatment and treatment samples of skin for vascular area, endothelial cell proliferation and apoptosis, or β3 integrin levels. Phosphorylated focal adhesion kinase (pFAK) was significantly diminished in skin wound vessels during MEDI-522 treatment compared to the pretreatment samples.

Conclusions: MEDI-522 was detectable both in quiescent and in angiogenically active skin blood vessels as well as in the dermal interstitial space. The levels of pFAK were reduced during MEDI-522 treatment, suggesting a modulating effect on this signaling molecule.

Keywords

Angiogenesis Integrin Phase I trial Focal adhesion kinase Wound healing 

Notes

Acknowledgments

Work supported by the National Cancer Institute, UO1 CA62491 (G. Wilding, PI) and NO2-CO-124001 (22XS082A; G. Wilding, PI) and by National Center for Research Resources, MO1 RR03186 (P.M. Farrell, PI).

References

  1. 1.
    Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571PubMedCrossRefGoogle Scholar
  2. 2.
    Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822PubMedGoogle Scholar
  3. 3.
    Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS (2001) Pilot study of vitaxin—an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 92:1347–1348PubMedCrossRefGoogle Scholar
  4. 4.
    Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056–3061PubMedGoogle Scholar
  5. 5.
    Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD (1998) Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci USA 95:6037–6042PubMedCrossRefGoogle Scholar
  6. 6.
    McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G (2005) Phase I trial of a monoclonal antibody specific for {alpha}v{beta}3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11:7851–7860PubMedCrossRefGoogle Scholar
  7. 7.
    Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, Thompson S, Williams KM, Klitzman B, Yuan F, Grichnik JM, Proia AD, Conway DA, Hurwitz HI (2003) Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 9:586–593PubMedGoogle Scholar
  8. 8.
    Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, Neider R, Sebree LA, Friedl A (2001) Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7:3366–3374PubMedGoogle Scholar
  9. 9.
    Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68PubMedCrossRefGoogle Scholar
  10. 10.
    Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164PubMedCrossRefGoogle Scholar
  11. 11.
    Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO (1999) Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103:229–238PubMedCrossRefGoogle Scholar
  12. 12.
    Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8:27–34PubMedCrossRefGoogle Scholar
  13. 13.
    Bader BL, Rayburn H, Crowley D, Hynes RO (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95:507–519PubMedCrossRefGoogle Scholar
  14. 14.
    Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918–921PubMedCrossRefGoogle Scholar
  15. 15.
    Cheresh DA, Stupack DG (2002) Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med 8:193–194PubMedCrossRefGoogle Scholar
  16. 16.
    Carmeliet P (2002) Integrin indecision. Nat Med 8:14–16PubMedCrossRefGoogle Scholar
  17. 17.
    Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256PubMedCrossRefGoogle Scholar
  18. 18.
    Parsons JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116:1409–1416PubMedCrossRefGoogle Scholar
  19. 19.
    Renshaw MW, Price LS, Schwartz MA (1999) Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. J Cell Biol 147:611–618PubMedCrossRefGoogle Scholar
  20. 20.
    Aplin AE, Short SM, Juliano RL (1999) Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains. J Biol Chem 274:31223–31228PubMedCrossRefGoogle Scholar
  21. 21.
    Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539–544PubMedCrossRefGoogle Scholar
  22. 22.
    Ilic D, Kovacic B, McDonagh S, Jin F, Baumbusch C, Gardner DG, Damsky CH (2003) Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res 92:300–307PubMedCrossRefGoogle Scholar
  23. 23.
    Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL (2005) Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 169:941–952PubMedCrossRefGoogle Scholar
  24. 24.
    Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840–850PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Dahua Zhang
    • 1
  • Thomas Pier
    • 1
  • Douglas G. McNeel
    • 2
  • George Wilding
    • 2
  • Andreas Friedl
    • 1
    • 2
    Email author
  1. 1.Department of Pathology and Laboratory MedicineUniversity of WisconsinMadisonUSA
  2. 2.University of Wisconsin Comprehensive Cancer CenterMadisonUSA

Personalised recommendations